Mesenchymal stem cells for the management of inflammation in osteoarthritis: State of the art and perspectives

Osteoarthritis and Cartilage

Volumn 23, Issue 11, 2015, Pages 2027-2035

  Pers, Y M ^a,b,c   Ruiz, M ^a,b   Noel D ^a,b   Jorgensen, C ^a,b,c  

^a HÔPITAL SAINT ELOI   (France)

^b UNIV MONTPELLIER   (France)

^c LAPEYRONIE HOSPITAL   (France)

Author keywords

Mesenchymal stem cells; MiRNA; Regenerative medicine; Rheumatic diseases; Trophic factors

Indexed keywords

5' NUCLEOTIDASE; CD11B ANTIGEN; CD14 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; COLLAGENASE 3; ENDOGLIN; HLA DR ANTIGEN; INTERSTITIAL COLLAGENASE; MICRORNA; STROMAL CELL DERIVED FACTOR 1; STROMELYSIN; THROMBOSPONDIN; THY 1 ANTIGEN;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICULAR CARTILAGE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CELL THERAPY; CHONDROGENESIS; HUMAN; IMMUNOMODULATION; IMMUNOPHENOTYPING; INFLAMMATION; MESENCHYMAL STEM CELL; NONHUMAN; OSTEOARTHRITIS; PHENOTYPE; PRIORITY JOURNAL; REGENERATIVE MEDICINE; REVIEW; SIGNAL TRANSDUCTION; STROMA CELL; TH1 CELL; TH17 CELL; TISSUE REGENERATION; TISSUE REPAIR; UPREGULATION; CYTOLOGY; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; PATHOLOGY; PROCEDURES; TISSUE ENGINEERING;

HUMANS; INFLAMMATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; OSTEOARTHRITIS; TISSUE ENGINEERING;

EID: 84945267704     PISSN: 10634584     EISSN: 15229653     Source Type: Journal    
DOI: 10.1016/j.joca.2015.07.004     Document Type: Review

References (111)

1. Hochberg M.C., Altman R.D., April K.T., Benkhalti M., Guyatt G., McGowan J., et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 2012, 64:465-474.
2. Zhang W., Moskowitz R.W., Nuki G., Abramson S., Altman R.D., Arden N., et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008, 16:137-162.
3. Chevalier X., Goupille P., Beaulieu A.D., Burch F.X., Bensen W.G., Conrozier T., et al. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2009, 61:344-352.
4. Chevalier X., Ravaud P., Maheu E., Baron G., Rialland A., Vergnaud P., et al. Adalimumab in patients with hand osteoarthritis refractory to analgesics and NSAIDs: a randomised, multicentre, double-blind, placebo-controlled trial. Ann Rheum Dis 2014 May 9, [Epub ahead of print]. 10.1136/annrheumdis-2014-205348.
5. Cohen S.B., Proudman S., Kivitz A.J., Burch F.X., Donohue J.P., Burstein D., et al. A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee. Arthritis Res Ther 2011, 13:R125.
6. Verbruggen G., Wittoek R., Vander Cruyssen B., Elewaut D. Tumour necrosis factor blockade for the treatment of erosive osteoarthritis of the interphalangeal finger joints: a double blind, randomised trial on structure modification. Ann Rheum Dis 2012, 71:891-898.
7. Chevalier X., Eymard F., Richette P. Biologic agents in osteoarthritis: hopes and disappointments. Nat Rev Rheumatol 2013, 9:400-410.
8. Liu-Bryan R., Terkeltaub R. Emerging regulators of the inflammatory process in osteoarthritis. Nat Rev Rheumatol 2015, 11:35-44.
9. van Lent P.L., Grevers L., Blom A.B., Sloetjes A., Mort J.S., Vogl T., et al. Myeloid-related proteins S100A8/S100A9 regulate joint inflammation and cartilage destruction during antigen-induced arthritis. Ann Rheum Dis 2008, 67:1750-1758.
10. Ritter S.Y., Subbaiah R., Bebek G., Crish J., Scanzello C.R., Krastins B., et al. Proteomic analysis of synovial fluid from the osteoarthritic knee: comparison with transcriptome analyses of joint tissues. Arthritis Rheum 2013, 65:981-992.
11. Schneider E.M., Du W., Fiedler J., Hogel J., Gunther K.P., Brenner H., et al. The (-765 G-->C) promoter variant of the COX-2/PTGS2 gene is associated with a lower risk for end-stage hip and knee osteoarthritis. Ann Rheum Dis 2011, 70:1458-1460.
12. Liu-Bryan R. Synovium and the innate inflammatory network in osteoarthritis progression. Curr Rheumatol Rep 2013, 15:323.
13. Jones E.A., English A., Henshaw K., Kinsey S.E., Markham A.F., Emery P., et al. Enumeration and phenotypic characterization of synovial fluid multipotential mesenchymal progenitor cells in inflammatory and degenerative arthritis. Arthritis Rheum 2004, 50:817-827.
14. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
15. Bianco P., Cao X., Frenette P.S., Mao J.J., Robey P.G., Simmons P.J., et al. The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine. Nat Med 2013, 19:35-42.
16. Mendez-Ferrer S., Michurina T.V., Ferraro F., Mazloom A.R., Macarthur B.D., Lira S.A., et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 2010, 466:829-834.
17. Ding L., Saunders T.L., Enikolopov G., Morrison S.J. Endothelial and perivascular cells maintain haematopoietic stem cells. Nature 2012, 481:457-462.
18. Sacchetti B., Funari A., Michienzi S., Di Cesare S., Piersanti S., Saggio I., et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell 2007, 131:324-336.
19. Worthley D.L., Churchill M., Compton J.T., Tailor Y., Rao M., Si Y., et al. Gremlin 1 identifies a skeletal stem cell with bone, cartilage, and reticular stromal potential. Cell 2015, 160:269-284.
20. Chan C.K., Seo E.Y., Chen J.Y., Lo D., McArdle A., Sinha R., et al. Identification and specification of the mouse skeletal stem cell. Cell 2015, 160:285-298.
21. Gnecchi M., He H., Noiseux N., Liang O.D., Zhang L., Morello F., et al. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. Faseb J 2006, 20:661-669.
22. Rehman J., Traktuev D., Li J., Merfeld-Clauss S., Temm-Grove C.J., Bovenkerk J.E., et al. Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation 2004, 109:1292-1298.
23. Usunier B., Benderitter M., Tamarat R., Chapel A. Management of fibrosis: the mesenchymal stromal cells breakthrough. Stem Cells Int 2014, 2014. 340257.
24. Jackson W.M., Nesti L.J., Tuan R.S. Mesenchymal stem cell therapy for attenuation of scar formation during wound healing. Stem Cell Res Ther 2012, 3:20.
25. Luz-Crawford P., Noel D., Fernandez X., Khoury M., Figueroa F., Carrion F., et al. Mesenchymal stem cells repress Th17 molecular program through the PD-1 pathway. PLoS One 2012, 7:e45272.
26. Luz-Crawford P., Kurte M., Bravo-Alegria J., Contreras R., Nova-Lamperti E., Tejedor G., et al. Mesenchymal stem cells generate a CD4+CD25+Foxp3+ regulatory T cell population during the differentiation process of Th1 and Th17 cells. Stem Cell Res Ther 2013, 4:65.
27. Bouffi C., Bony C., Courties G., Jorgensen C., Noel D. IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis. PLoS One 2010, 5:e14247.
28. Bouffi C., Bony C., Jorgensen C., Noel D. Skin fibroblasts are potent suppressors of inflammation in experimental arthritis. Ann Rheum Dis 2011, 70:1671-1676.
29. van der Meel R., Fens M.H., Vader P., van Solinge W.W., Eniola-Adefeso O., Schiffelers R.M. Extracellular vesicles as drug delivery systems: lessons from the liposome field. J Control Release 2014, 195:72-85.
30. Akyurekli C., Le Y., Richardson R.B., Fergusson D., Tay J., Allan D.S. A systematic review of preclinical studies on the therapeutic potential of mesenchymal stromal cell-derived microvesicles. Stem Cell Rev 2015, 11:150-160.
31. Maumus M., Jorgensen C., Noel D. Mesenchymal stem cells in regenerative medicine applied to rheumatic diseases: role of secretome and exosomes. Biochimie 2013, 95:2229-2234.
32. Klyushnenkova E., Mosca J.D., Zernetkina V., Majumdar M.K., Beggs K.J., Simonetti D.W., et al. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci 2005, 12:47-57.
33. Augello A., Tasso R., Negrini S.M., Cancedda R., Pennesi G. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum 2007, 56:1175-1186.
34. Gonzalez M.A., Gonzalez-Rey E., Rico L., Buscher D., Delgado M. Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis Rheum 2009, 60:1006-1019.
35. Zhou B., Yuan J., Zhou Y., Ghawji M., Deng Y.P., Lee A.J., et al. Administering human adipose-derived mesenchymal stem cells to prevent and treat experimental arthritis. Clin Immunol 2011, 141:328-337.
36. Barry F., Murphy M. Mesenchymal stem cells in joint disease and repair. Nat Rev Rheumatol 2013, 9:584-594.
37. Hoogduijn M.J., Roemeling-van Rhijn M., Engela A.U., Korevaar S.S., Mensah F.K., Franquesa M., et al. Mesenchymal stem cells induce an inflammatory response after intravenous infusion. Stem Cells Dev 2013, 22:2825-2835.
38. Roemeling-van Rhijn M., Reinders M.E., Franquesa M., Engela A.U., Korevaar S.S., Roelofs H., et al. Human allogeneic bone marrow and adipose tissue derived mesenchymal stromal cells induce CD8+ cytotoxic T cell reactivity. J Stem Cell Res Ther 2013, 3:004.
39. Ankrum J.A., Ong J.F., Karp J.M. Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol 2014, 32:252-260.
40. Bustos M.L., Huleihel L., Meyer E.M., Donnenberg A.D., Donnenberg V.S., Sciurba J.D., et al. Activation of human mesenchymal stem cells impacts their therapeutic abilities in lung injury by increasing interleukin (IL)-10 and IL-1RN levels. Stem Cells Transl Med 2013, 2:884-895.
41. Treacy O., O'Flynn L., Ryan A.E., Morcos M., Lohan P., Schu S., et al. Mesenchymal stem cell therapy promotes corneal allograft survival in rats by local and systemic immunomodulation. Am J Transpl 2014, 14:2023-2036.
42. Papadopoulou A., Yiangou M., Athanasiou E., Zogas N., Kaloyannidis P., Batsis I., et al. Mesenchymal stem cells are conditionally therapeutic in preclinical models of rheumatoid arthritis. Ann Rheum Dis 2012, 71:1733-1740.
43. Yoshimura H., Muneta T., Nimura A., Yokoyama A., Koga H., Sekiya I. Comparison of rat mesenchymal stem cells derived from bone marrow, synovium, periosteum, adipose tissue, and muscle. Cell Tissue Res 2007, 327:449-462.
44. Dimarino A.M., Caplan A.I., Bonfield T.L. Mesenchymal stem cells in tissue repair. Front Immunol 2013, 4:201.
45. Jones E., English A., Churchman S.M., Kouroupis D., Boxall S.A., Kinsey S., et al. Large-scale extraction and characterization of CD271+ multipotential stromal cells from trabecular bone in health and osteoarthritis: implications for bone regeneration strategies based on uncultured or minimally cultured multipotential stromal cells. Arthritis Rheum 2010, 62:1944-1954.
46. Murphy J.M., Dixon K., Beck S., Fabian D., Feldman A., Barry F. Reduced chondrogenic and adipogenic activity of mesenchymal stem cells from patients with advanced osteoarthritis. Arthritis Rheum 2002, 46:704-713.
47. Prockop D.J. Concise review: two negative feedback loops place mesenchymal stem/stromal cells at the center of early regulators of inflammation. Stem Cells 2013, 31:2042-2046.
48. Galipeau J. The mesenchymal stromal cells dilemma-does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road?. Cytotherapy 2013, 15:2-8.
49. von Bahr L., Sundberg B., Lonnies L., Sander B., Karbach H., Hagglund H., et al. Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. Biol Blood Marrow Transpl 2012, 18:557-564.
50. Djouad F., Bouffi C., Ghannam S., Noel D., Jorgensen C. Mesenchymal stem cells: innovative therapeutic tools for rheumatic diseases. Nat Rev Rheumatol 2009, 5:392-399.
51. Mazor M., Lespessailles E., Coursier R., Daniellou R., Best T.M., Toumi H. Mesenchymal stem-cell potential in cartilage repair: an update. J Cell Mol Med 2014, 18:2340-2350.
52. Bornes T.D., Adesida A.B., Jomha N.M. Mesenchymal stem cells in the treatment of traumatic articular cartilage defects: a comprehensive review. Arthritis Res Ther 2014, 16:432.
53. Wakitani S., Imoto K., Yamamoto T., Saito M., Murata N., Yoneda M. Human autologous culture expanded bone marrow mesenchymal cell transplantation for repair of cartilage defects in osteoarthritic knees. Osteoarthritis Cartilage 2002, 10:199-206.
54. Ringe J., Burmester G.R., Sittinger M. Regenerative medicine in rheumatic disease-progress in tissue engineering. Nat Rev Rheumatol 2012, 8:493-498.
55. Ryu J.S., Jung Y.H., Cho M.Y., Yeo J.E., Choi Y.J., Kim Y.I., et al. Co-culture with human synovium-derived mesenchymal stem cells inhibits inflammatory activity and increases cell proliferation of sodium nitroprusside-stimulated chondrocytes. Biochem Biophys Res Commun 2014, 447:715-720.
56. Wu L., Leijten J., van Blitterswijk C.A., Karperien M. Fibroblast growth factor-1 is a mesenchymal stromal cell-secreted factor stimulating proliferation of osteoarthritic chondrocytes in co-culture. Stem Cells Dev 2013, 22:2356-2367.
57. Manferdini C., Maumus M., Gabusi E., Piacentini A., Filardo G., Peyrafitte J.A., et al. Adipose-derived mesenchymal stem cells exert antiinflammatory effects on chondrocytes and synoviocytes from osteoarthritis patients through prostaglandin E2. Arthritis Rheum 2013, 65:1271-1281.
58. Maumus M., Manferdini C., Toupet K., Peyrafitte J.A., Ferreira R., Facchini A., et al. Adipose mesenchymal stem cells protect chondrocytes from degeneration associated with osteoarthritis. Stem Cell Res 2013, 11:834-844.
59. Jorgensen C., Noel D. Mesenchymal stem cells in osteoarticular diseases. Regen Med 2011, 6:44-51.
60. Lohan P., Coleman C.M., Murphy J.M., Griffin M.D., Ritter T., Ryan A.E. Changes in immunological profile of allogeneic mesenchymal stem cells after differentiation: should we be concerned?. Stem Cell Res Ther 2014, 5:99.
61. Zheng Z.H., Li X.Y., Ding J., Jia J.F., Zhu P. Allogeneic mesenchymal stem cell and mesenchymal stem cell-differentiated chondrocyte suppress the responses of type II collagen-reactive T cells in rheumatoid arthritis. Rheumatology (Oxford) 2008, 47:22-30.
62. Chen X., McClurg A., Zhou G.Q., McCaigue M., Armstrong M.A., Li G. Chondrogenic differentiation alters the immunosuppressive property of bone marrow-derived mesenchymal stem cells, and the effect is partially due to the upregulated expression of B7 molecules. Stem Cells 2007, 25:364-370.
63. Ryan A.E., Lohan P., O'Flynn L., Treacy O., Chen X., Coleman C., et al. Chondrogenic differentiation increases antidonor immune response to allogeneic mesenchymal stem cell transplantation. Mol Ther 2014, 22:655-667.
64. Ter Huurne M., Schelbergen R., Blattes R., Blom A., de Munter W., Grevers L.C., et al. Antiinflammatory and chondroprotective effects of intraarticular injection of adipose-derived stem cells in experimental osteoarthritis. Arthritis Rheum 2012, 64:3604-3613.
65. Schelbergen R.F., van Dalen S., Ter Huurne M., Roth J., Vogl T., Noel D., et al. Treatment efficacy of adipose-derived stem cells in experimental osteoarthritis is driven by high synovial activation and reflected by S100A8/A9 serum levels. Osteoarthritis Cartilage 2014, 22:1158-1166.
66. Desando G., Cavallo C., Sartoni F., Martini L., Parrilli A., Veronesi F., et al. Intra-articular delivery of adipose derived stromal cells attenuates osteoarthritis progression in an experimental rabbit model. Arthritis Res Ther 2013, 15:R22.
67. Shen W., Chen J., Zhu T., Yin Z., Chen X., Chen L., et al. Osteoarthritis prevention through meniscal regeneration induced by intra-articular injection of meniscus stem cells. Stem Cells Dev 2013, 22:2071-2082.
68. Diekman B.O., Wu C.L., Louer C.R., Furman B.D., Huebner J.L., Kraus V.B., et al. Intra-articular delivery of purified mesenchymal stem cells from C57BL/6 or MRL/MpJ superhealer mice prevents posttraumatic arthritis. Cell Transpl 2013, 22:1395-1408.
69. Shen W., Chen J., Zhu T., Chen L., Zhang W., Fang Z., et al. Intra-articular injection of human meniscus stem/progenitor cells promotes meniscus regeneration and ameliorates osteoarthritis through stromal cell-derived factor-1/CXCR4-mediated homing. Stem Cells Transl Med 2014, 3:387-394.
70. Ambros V. microRNAs: tiny regulators with great potential. Cell 2001, 107:823-826.
71. Clark E.A., Kalomoiris S., Nolta J.A., Fierro F.A. Concise review: MicroRNA function in multipotent mesenchymal stromal cells. Stem Cells 2014, 32:1074-1082.
72. Oskowitz A.Z., Lu J., Penfornis P., Ylostalo J., McBride J., Flemington E.K., et al. Human multipotent stromal cells from bone marrow and microRNA: regulation of differentiation and leukemia inhibitory factor expression. Proc Natl Acad Sci USA 2008, 105:18372-18377.
73. Kobayashi T., Lu J., Cobb B.S., Rodda S.J., McMahon A.P., Schipani E., et al. Dicer-dependent pathways regulate chondrocyte proliferation and differentiation. Proc Natl Acad Sci USA 2008, 105:1949-1954.
74. Guerit D., Brondello J.M., Chuchana P., Philipot D., Toupet K., Bony C., et al. FOXO3A regulation by miRNA-29a controls chondrogenic differentiation of mesenchymal stem cells and cartilage formation. Stem Cells Dev 2014, 23:1195-1205.
75. Guerit D., Philipot D., Chuchana P., Toupet K., Brondello J.M., Mathieu M., et al. Sox9-regulated miRNA-574-3p inhibits chondrogenic differentiation of mesenchymal stem cells. PLoS One 2013, 8:e62582.
76. Karlsen T.A., Jakobsen R.B., Mikkelsen T.S., Brinchmann J.E. microRNA-140 targets RALA and regulates chondrogenic differentiation of human mesenchymal stem cells by translational enhancement of SOX9 and ACAN. Stem Cells Dev 2014, 23:290-304.
77. Lin E.A., Kong L., Bai X.H., Luan Y., Liu C.J. miR-199a, a bone morphogenic protein 2-responsive MicroRNA, regulates chondrogenesis via direct targeting to Smad1. J Biol Chem 2009, 284:11326-11335.
78. Ham O., Lee C.Y., Song B.W., Lee S.Y., Kim R., Park J.H., et al. Upregulation of miR-23b enhances the autologous therapeutic potential for degenerative arthritis by targeting PRKACB in synovial fluid-derived mesenchymal stem cells from patients. Mol Cells 2014, 37:449-456.
79. Xu J., Kang Y., Liao W.M., Yu L. MiR-194 regulates chondrogenic differentiation of human adipose-derived stem cells by targeting Sox5. PLoS One 2012, 7:e31861.
80. Chen K.D., Goto S., Hsu L.W., Lin T.Y., Nakano T., Lai C.Y., et al. Identification of miR-27b as a novel signature from the mRNA profiles of adipose-derived mesenchymal stem cells involved in the tolerogenic response. PLoS One 2013, 8:e60492.
81. Liu L., Wang Y., Fan H., Zhao X., Liu D., Hu Y., et al. MicroRNA-181a regulates local immune balance by inhibiting proliferation and immunosuppressive properties of mesenchymal stem cells. Stem Cells 2012, 30:1756-1770.
82. Xu C., Ren G., Cao G., Chen Q., Shou P., Zheng C., et al. miR-155 regulates immune modulatory properties of mesenchymal stem cells by targeting TAK1-binding protein 2. J Biol Chem 2013, 288:11074-11079.
83. Xu J., Wu W., Zhang L., Dorset-Martin W., Morris M.W., Mitchell M.E., et al. The role of microRNA-146a in the pathogenesis of the diabetic wound-healing impairment: correction with mesenchymal stem cell treatment. Diabetes 2012, 61:2906-2912.
84. Matysiak M., Fortak-Michalska M., Szymanska B., Orlowski W., Jurewicz A., Selmaj K. MicroRNA-146a negatively regulates the immunoregulatory activity of bone marrow stem cells by targeting prostaglandin E2 synthase-2. J Immunol 2013, 190:5102-5109.
85. Miyaki S., Sato T., Inoue A., Otsuki S., Ito Y., Yokoyama S., et al. MicroRNA-140 plays dual roles in both cartilage development and homeostasis. Genes Dev 2010, 24:1173-1185.
86. Martinez-Sanchez A., Dudek K.A., Murphy C.L. Regulation of human chondrocyte function through direct inhibition of cartilage master regulator SOX9 by microRNA-145 (miRNA-145). J Biol Chem 2012, 287:916-924.
87. Taganov K.D., Boldin M.P., Chang K.J., Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 2006, 103:12481-12486.
88. Nagata Y., Nakasa T., Mochizuki Y., Ishikawa M., Miyaki S., Shibuya H., et al. Induction of apoptosis in the synovium of mice with autoantibody-mediated arthritis by the intraarticular injection of double-stranded MicroRNA-15a. Arthritis Rheum 2009, 60:2677-2683.
89. Iliopoulos D., Malizos K.N., Oikonomou P., Tsezou A. Integrative microRNA and proteomic approaches identify novel osteoarthritis genes and their collaborative metabolic and inflammatory networks. PLoS One 2008, 3:e3740.
90. Jones S.W., Watkins G., Le Good N., Roberts S., Murphy C.L., Brockbank S.M., et al. The identification of differentially expressed microRNA in osteoarthritic tissue that modulate the production of TNF-alpha and MMP13. Osteoarthritis Cartilage 2009, 17:464-472.
91. Abouheif M.M., Nakasa T., Shibuya H., Niimoto T., Kongcharoensombat W., Ochi M. Silencing microRNA-34a inhibits chondrocyte apoptosis in a rat osteoarthritis model in vitro. Rheumatology (Oxford) 2010, 49:2054-2060.
92. Diaz-Prado S., Cicione C., Muinos-Lopez E., Hermida-Gomez T., Oreiro N., Fernandez-Lopez C., et al. Characterization of microRNA expression profiles in normal and osteoarthritic human chondrocytes. BMC Musculoskelet Disord 2012, 13:144.
93. Philipot D., Guerit D., Platano D., Chuchana P., Olivotto E., Espinoza F., et al. p16INK4a and its regulator miR-24 link senescence and chondrocyte terminal differentiation-associated matrix remodeling in osteoarthritis. Arthritis Res Ther 2014, 16:R58.
94. Yamasaki K., Nakasa T., Miyaki S., Ishikawa M., Deie M., Adachi N., et al. Expression of MicroRNA-146a in osteoarthritis cartilage. Arthritis Rheum 2009, 60:1035-1041.
95. Miyaki S., Nakasa T., Otsuki S., Grogan S.P., Higashiyama R., Inoue A., et al. MicroRNA-140 is expressed in differentiated human articular chondrocytes and modulates interleukin-1 responses. Arthritis Rheum 2009, 60:2723-2730.
96. Tsezou A. Osteoarthritis year in review 2014: genetics and genomics. Osteoarthritis Cartilage 2014, 22:2017-2024.
97. Beyer C., Zampetaki A., Lin N.Y., Kleyer A., Perricone C., Iagnocco A., et al. Signature of circulating microRNAs in osteoarthritis. Ann Rheum Dis 2015, 74:e18.
98. Pers Y.M., Jorgensen C. MicroRNA in 2012: biotherapeutic potential of microRNAs in rheumatic diseases. Nat Rev Rheumatol 2013, 9:76-78.
99. Nejadnik H., Hui J.H., Feng Choong E.P., Tai B.C., Lee E.H. Autologous bone marrow-derived mesenchymal stem cells versus autologous chondrocyte implantation: an observational cohort study. Am J Sports Med 2010, 38:1110-1116.
100. Wakitani S., Nawata M., Tensho K., Okabe T., Machida H., Ohgushi H. Repair of articular cartilage defects in the patello-femoral joint with autologous bone marrow mesenchymal cell transplantation: three case reports involving nine defects in five knees. J Tissue Eng Regen Med 2007, 1:74-79.
101. Saw K.Y., Anz A., Siew-Yoke Jee C., Merican S., Ching-Soong Ng R., Roohi S.A., et al. Articular cartilage regeneration with autologous peripheral blood stem cells versus hyaluronic acid: a randomized controlled trial. Arthroscopy 2013, 29:684-694.
102. Giannini S., Buda R., Battaglia M., Cavallo M., Ruffilli A., Ramponi L., et al. One-step repair in talar osteochondral lesions: 4-year clinical results and t2-mapping capability in outcome prediction. Am J Sports Med 2013, 41:511-518.
103. Wakitani S., Okabe T., Horibe S., Mitsuoka T., Saito M., Koyama T., et al. Safety of autologous bone marrow-derived mesenchymal stem cell transplantation for cartilage repair in 41 patients with 45 joints followed for up to 11 years and 5 months. J Tissue Eng Regen Med 2011, 5:146-150.
104. Davatchi F., Abdollahi B.S., Mohyeddin M., Shahram F., Nikbin B. Mesenchymal stem cell therapy for knee osteoarthritis. Preliminary report of four patients. Int J Rheum Dis 2011, 14:211-215.
105. Emadedin M., Aghdami N., Taghiyar L., Fazeli R., Moghadasali R., Jahangir S., et al. Intra-articular injection of autologous mesenchymal stem cells in six patients with knee osteoarthritis. Arch Iran Med 2012, 15:422-428.
106. Koh Y.G., Choi Y.J., Kwon O.R., Kim Y.S. Second-look arthroscopic evaluation of cartilage lesions after mesenchymal stem cell implantation in osteoarthritic knees. Am J Sports Med 2014, 42:1628-1637.
107. Jo C.H., Lee Y.G., Shin W.H., Kim H., Chai J.W., Jeong E.C., et al. Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a proof-of-concept clinical trial. Stem Cells 2014, 32:1254-1266.
108. Orozco L., Munar A., Soler R., Alberca M., Soler F., Huguet M., et al. Treatment of knee osteoarthritis with autologous mesenchymal stem cells: two-year follow-up results. Transplantation 2014, 97:e66-68.
109. Cheng A., Kapacee Z., Peng J., Lu S., Lucas R.J., Hardingham T.E., et al. Cartilage repair using human embryonic stem cell-derived chondroprogenitors. Stem Cells Transl Med 2014, 3:1287-1294.
110. Willard V.P., Diekman B.O., Sanchez-Adams J., Christoforou N., Leong K.W., Guilak F. Use of cartilage derived from murine induced pluripotent stem cells for osteoarthritis drug screening. Arthritis Rheumatol 2014, 66:3062-3072.
111. Lee J., Kim Y., Yi H., Diecke S., Kim J., Jung H., et al. Generation of disease-specific induced pluripotent stem cells from patients with rheumatoid arthritis and osteoarthritis. Arthritis Res Ther 2014, 16:R41.